文献速递血栓与止血

异柠檬酸脱氢酶1(IDH1)突变与脑肿瘤中平足蛋白表达联合识别静脉血栓栓塞高风险或低风险患者

Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism.
PubMed 文献 · J Thromb Haemost · 2018-05-20

前瞻性队列研究在脑肿瘤标本中检测IDH1 R132H突变与平足蛋白表达,随访2年观察症状性静脉血栓栓塞(VTE)。IDH1野生型且平足蛋白高表达者6个月VTE风险为18.2%,IDH1突变且无平足蛋白表达者为0%,两者似互斥。

要点

  • IDH1野生型且平足蛋白中高表达脑肿瘤患者6个月VTE风险为18.2%。
  • IDH1突变且无平足蛋白表达脑肿瘤患者6个月VTE风险为0%。
  • IDH1突变与平足蛋白过表达在原发性脑肿瘤中似乎互斥。

核心结论

  • IDH1突变与平足蛋白过表达似乎互斥,IDH1突变脑肿瘤患者VTE风险极低,而IDH1野生型患者VTE风险与平足蛋白表达水平密切相关。

研究设计与样本

  • 前瞻性队列研究,对脑肿瘤标本(主要为胶质瘤)通过免疫组化检测肿瘤内IDH1 R132H突变和平足蛋白,主要终点为2年随访期间的症状性VTE。

主要发现

  • 所有中等至高度表达平足蛋白的脑肿瘤也显示IDH1野生型状态。
  • 基于IDH1状态和平足蛋白表达水平的评分可预测VTE风险。
  • IDH1野生型且平足蛋白高表达患者较IDH1突变且无平足蛋白表达患者6个月VTE风险显著增高(18.2% vs. 0%)。

关键数值与推荐

  • IDH1野生型且平足蛋白高表达脑肿瘤患者6个月VTE风险为18.2%。
  • IDH1突变且无平足蛋白表达脑肿瘤患者6个月VTE风险为0%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Risk stratification for venous thromboembolism (VTE) in patients with brain tumors is challenging. Patients with IDH1 wildtype and high podoplanin expression have a 6-month VTE risk of 18.2%. Patients with IDH1 mutation and no podoplanin expression have a 6-month VTE risk of 0%. IDH1 mutation and podoplanin overexpression in primary brain tumors appear to be exclusive. SUMMARY: Background Venous thromboembolism (VTE) is a frequent complication in primary brain tumor patients. Independent studies revealed that podoplanin expression in brain tumors is associated with increased VTE risk, whereas the isocitrate dehydrogenase 1 (IDH1) mutation is associated with very low VTE risk. Objectives To investigate the interrelation between intratumoral podoplanin expression and IDH1 mutation, and their mutual impact on VTE development. Patients/Methods In a prospective cohort study, intratumoral IDH1 R132H mutation and podoplanin were determined in brain tumor specimens (mainly glioma) by immunohistochemistry. The primary endpoint of the study was symptomatic VTE during a 2-year follow-up. Results All brain tumors that expressed podoplanin to a medium-high extent showed also an IDH1 wild-type status. A score based on IDH1 status and podoplanin expression levels allowed prediction of the risk of VTE. Patients with wild-type IDH1 brain tumors and high podoplanin expression had a significantly increased VTE risk compared with those with mutant IDH1 tumors and no podoplanin expression (6-month risk 18.2% vs. 0%). Conclusions IDH1 mutation and podoplanin overexpression seem to be exclusive. Although brain tumor patients with IDH1 mutation are at very low risk of VTE, the risk of VTE in patients with IDH1 wild-type tumors is strongly linked to podoplanin expression levels.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Mir Seyed Nazari P, Riedl J, Preusser M, et al. Combination of isocitrate dehydrogenase 1 (IDH1) mutation and podoplanin expression in brain tumors identifies patients at high or low risk of venous thromboembolism. J Thromb Haemost. 2018. PMID: 29676036. doi:10.1111/jth.14129

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。